Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AML

Andrew Wei, MBBS, PhD
Published: Thursday, Mar 30, 2017



Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

A phase I trial was conducted to answer the question of whether targeting BCL-2 would be effective in AML.

Venetoclax was combined with low-dose chemotherapy to see whether the combination would raise response rates in relapsed/refractory patients. The combination was very well tolerated, with few severe side effects being reported.
 


Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

A phase I trial was conducted to answer the question of whether targeting BCL-2 would be effective in AML.

Venetoclax was combined with low-dose chemotherapy to see whether the combination would raise response rates in relapsed/refractory patients. The combination was very well tolerated, with few severe side effects being reported.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x